StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)

Close on Nov 17, 2026Market cap $907.15MP/E –Yield –

Aktis Oncology profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-766.7%+362.3
Q2 FY2026Jun 30, 2026-713.5%+322.1
Q1 FY2026Mar 31, 2026-567.9%–
Q3 FY2025Sep 30, 2025-983.7%–
Q2 FY2025Jun 30, 2025-1129.0%–
Q1 FY2025Mar 31, 2025-1035.6%–

More Aktis Oncology figures

See a number that looks wrong?